| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,552,000 |
| Market
Cap: |
3.04(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.07 - $59.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 8.6 |
|
| Guru Rank Number : 538 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
| Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
5,981 |
52,172 |
114,858 |
280,340 |
| Total Sell Value |
$151,224 |
$1,447,501 |
$4,819,149 |
$12,887,777 |
| Total People Sold |
3 |
8 |
10 |
15 |
| Total Sell Transactions |
4 |
26 |
35 |
88 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schmertzler Michael |
|
– • – |
2023-06-07 |
4 |
AS |
$44.86 |
$44,860 |
D/D |
(1,000) |
116,766 |
|
-54% |
|
| Golden Lee Scott |
Chief Medical Officer |
• – – |
2023-06-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,286 |
|
-55% |
|
| Bell William F. Jr. |
|
– • – |
2023-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,333 |
6,333 |
|
- |
|
| Reeve Emma |
|
– • – |
2023-05-23 |
4 |
AS |
$59.52 |
$157,885 |
D/D |
(2,652) |
7,200 |
|
-64% |
|
| Reeve Emma |
|
– • – |
2023-05-23 |
4 |
OE |
$33.02 |
$88,520 |
D/D |
2,652 |
8,602 |
|
- |
|
| Reeve Emma |
|
– • – |
2023-05-22 |
4 |
AS |
$59.52 |
$423,630 |
D/D |
(7,116) |
7,200 |
|
-62% |
|
| Reeve Emma |
|
– • – |
2023-05-22 |
4 |
OE |
$33.02 |
$237,484 |
D/D |
7,116 |
11,148 |
|
- |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2023-05-22 |
4 |
AS |
$58.98 |
$118,791 |
D/D |
(2,013) |
47,553 |
|
-62% |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2023-05-19 |
4 |
AS |
$58.96 |
$377,491 |
D/D |
(6,403) |
49,566 |
|
-61% |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2023-05-18 |
4 |
AS |
$58.71 |
$46,267 |
D/D |
(788) |
55,969 |
|
-60% |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2023-05-17 |
4 |
AS |
$58.50 |
$470,822 |
D/D |
(8,048) |
56,757 |
|
-61% |
|
| Jacobson Allan Steven |
|
– • – |
2023-05-11 |
4 |
AS |
$54.78 |
$1,266,930 |
D/D |
(23,000) |
12,348 |
|
-53% |
|
| Jacobson Allan Steven |
|
– • – |
2023-05-11 |
4 |
OE |
$10.85 |
$249,550 |
D/D |
23,000 |
35,348 |
|
- |
|
| Reeve Emma |
|
– • – |
2023-04-21 |
4 |
AS |
$55.04 |
$238,258 |
D/D |
(4,328) |
7,200 |
|
-26% |
|
| Utter Christine Marie |
SVP, FINANCE & CAO |
• – – |
2023-04-21 |
4 |
AS |
$55.05 |
$258,326 |
D/D |
(4,692) |
38,059 |
|
-26% |
|
| Utter Christine Marie |
SVP, FINANCE & CAO |
• – – |
2023-04-21 |
4 |
OE |
$33.02 |
$154,930 |
D/D |
4,692 |
38,430 |
|
- |
|
| Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
• – – |
2023-04-18 |
4 |
S |
$52.04 |
$63,025 |
D/D |
(1,211) |
102,645 |
|
25% |
|
| Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
• – – |
2023-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
103,856 |
|
- |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2023-04-18 |
4 |
S |
$52.04 |
$38,096 |
D/D |
(732) |
64,805 |
|
25% |
|
| Boulding Mark Elliott |
EXEC. VP AND CLO |
• – – |
2023-04-17 |
4 |
AS |
$51.42 |
$3,183,830 |
D/D |
(61,923) |
75,378 |
|
-24% |
|
| Boulding Mark Elliott |
EXEC. VP AND CLO |
• – – |
2023-04-17 |
4 |
OE |
$30.86 |
$1,910,944 |
D/D |
61,923 |
134,009 |
|
- |
|
| Southwell David P |
|
– • – |
2023-04-17 |
4 |
AS |
$50.69 |
$583,187 |
D/D |
(11,429) |
10,500 |
|
-24% |
|
| Southwell David P |
|
– • – |
2023-04-17 |
4 |
OE |
$18.01 |
$205,836 |
D/D |
11,429 |
21,929 |
|
- |
|
| Hill Emily Luisa |
CHIEF FINANCIAL OFFICER |
• – – |
2023-03-27 |
4 |
AS |
$45.00 |
$331,335 |
D/D |
(7,363) |
38,925 |
|
-15% |
|
| Southwell David P |
|
– • – |
2023-03-27 |
4 |
AS |
$44.71 |
$450,956 |
D/D |
(10,000) |
10,500 |
|
-15% |
|
524 Records found
|
|
Page 3 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.54 (1.58%) 
